OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

Le résumé fourni par la source

Background: Biologic therapy efficacy and eligibility in severe asthma can vary by inflammatory phenotype. Tezepelumab targets TSLP, an epithelial cytokine implicated in both allergic and eosinophilic inflammation. Aims and Objectives: This post hoc analysis of the phase 3b WAYFINDER study of tezepelumab in oral corticosteroid (OCS)-dependent patients with severe asthma ( NCT05274815 ) evaluated maintenance OCS (mOCS) reduction by the presence of allergy and blood eosinophilia. Methods: WAYFINDER was a single-arm, OCS-sparing study in adults with severe asthma receiving mOCS. Patients received tezepelumab 210 mg every 4 weeks for up to 52 weeks. The co-primary endpoints were the proportions of patients who, without loss of asthma control: 1) reduced their mOCS dose to ≤5 mg/day; and 2) discontinued mOCS. Here, these endpoints were assessed in patients with or without allergy (FEIA+) and by baseline blood eosinophil count (BEC; <300 and ≥300 cells/μL). Results: mOCS dose reduction and discontinuation were seen across all subgroups at week 52; the highest proportion of patients meeting each of the co-primary endpoints was in the allergic/BEC ≥300 cells/μL group (Figure). Conclusions: Tezepelumab enabled patients with severe asthma across different inflammatory phenotypes to reduce or discontinue mOCS without loss of asthma control, with the greatest efficacy in those with allergic, eosinophilic asthma. erj;66/suppl_69/PA2485/F1 F1 F1

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.